WOBURN, Mass.--(BUSINESS WIRE)--ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced a significant expansion of its clinical study of the BioCart™ Cartilage Regeneration System. The randomized, double-arm, open-label, multicenter Phase II study comparing the safety and efficacy of the BioCart™ System to microfracture for the treatment of symptomatic cartilage defects. ProChon will have ten clinical study sites in the US and Israel by end of this year.
